{"nctId":"NCT00688740","briefTitle":"Docetaxel in Node Positive Adjuvant Breast Cancer","startDateStruct":{"date":"1997-06"},"conditions":["Breast Cancer"],"count":1491,"armGroups":[{"label":"TAC (Docetaxel)","type":"EXPERIMENTAL","interventionNames":["Drug: Docetaxel","Drug: Doxorubicin","Drug: Cyclophosphamide"]},{"label":"FAC (5-fluorouracil)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: 5-fluorouracil","Drug: Doxorubicin","Drug: Cyclophosphamide"]}],"interventions":[{"name":"Docetaxel","otherNames":["TaxotereÂ®"]},{"name":"5-fluorouracil","otherNames":["5-FU"]},{"name":"Doxorubicin","otherNames":[]},{"name":"Cyclophosphamide","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically proven breast cancer (invasive adenocarcinoma with at least one axillary lymph node showing evidence of tumor among a minimum of six resected lymph nodes).\n* Definitive surgical treatment must be either mastectomy, or breast conserving surgery with axillary lymph node dissection for operable breast cancer. Margins of resected specimen from definitive surgery must be histologically free of invasive adenocarcinoma and ductal carcinoma.\n\nExclusion criteria:\n\n* Prior systemic anticancer therapy for breast cancer (immunotherapy, hormonotherapy, chemotherapy).\n* Prior anthracycline therapy or taxoids (paclitaxel, docetaxel) for any malignancy.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Disease-Free Survival Events","description":"Disease-Free Survival (DFS)- are defined as local, regional or metastatic relapse or the date of second primary cancer or death from any cause whichever occurs first.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"287","spread":null},{"groupId":"OG001","value":"333","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Overall Survival Events","description":"Overall Survival - time from the date of randomization up to the date of death of any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"188","spread":null},{"groupId":"OG001","value":"241","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Second Primary Malignancies (Toxicity)","description":"Toxicity (second primary malignancies)- defined as histopathologically proven cancer, excluding nonmelanomatous skin cancer, in situ carcinoma of the cervix, and in situ carcinoma of the breast.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":267,"n":744},"commonTop":["Any skin and subcutaneous tissue disorders","Alopecia","Any gastrointestinal disorders","Any general disorders and administration site conditions","Nausea"]}}}